上海现代制药股份有限公司 董事会审计与风险管理委员会年报工作规程 （2025 年 8 月 28 日经八届二十三次董事会审议修订） 第一条 为促进上海现代制药股份有限公司（以下简称公司）规范运作，完 善公司治理机制，加强内部控制建设，充分发挥董事会审计与风险管理委员会 的科学决策和监督作用，确保对公司年度审计工作的有效监督，保护投资者合 法权益，根据中国证券监督管理委员会（以下简称中国证监会）、上海证券交 易所的有关规定及《上海现代制药股份有限公司章程》（以下简称《公司章 程》）等其他公司有关制度，制定本规程。 第二条 审计与风险管理委员会对公司董事会负责，委员会形成的决议和意 见视要求提交董事会审议。 审计与风险管理委员会委员应在公司年报编制和披露过程中充分发挥监督 作用，勤勉尽责，保持审计的独立性，维护公司整体利益。 第三条 审计与风险管理委员会在公司年报审计过程中，应履行如下主要职 责： （六）中国证监会、上海证券交易所等规定的其他职责。 第四条 公司及年审会计师事务所向审计与风险管理委员会提供的审计证据 应当具备充分性、相关性和可靠性。 第五条 审计与风险管理委员会应在年审会计师事务所进场前通过临时会议 ...

上海现代制药股份有限公司 股权投资管理办法 （2025年8月28日经八届二十三次董事会审议修订） 第一章 总则 第一条 为贯彻落实上海现代制药股份有限公司（以下简称公司）发展战 略，实现战略目标，规范股权投资行为，提高股权投资效益，防范股权投资风险， 根据《中华人民共和国公司法》《中华人民共和国企业国有资产法》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引第1号—规范运 作》《中央企业投资监督管理办法》《中央企业境外投资监督管理办法》等法律 法规及《上海现代制药股份有限公司章程》（以下简称《公司章程》）的相关规 定，制定本办法。 第二条 本办法适用于公司及公司所属全级次全资、控股子公司以及通过 股东协议、公司章程、董事会决议或其他协议安排拥有实际控制权的企业（以下 统称为"投资单位"）的境内、境外投资事项。 第三条 本办法所称境内、境外投资事项包括： （一）设立分/子公司（含分公司、全资及控股公司、参股公司）； （二）投资单位对子公司（含全资及控股）、参股公司增资或减资，以及放 弃同比例增资或减资； （三）通过收购、增资扩股、债转股、资产置换、无偿划转等方式取得投资 对象股权或产权； （ ...

上海现代制药股份有限公司 投资者关系管理制度 （2025 年 8 月 28 日经八届二十三次董事会审议修订） 第一章 总则 第一条 为规范上海现代制药股份有限公司(以下简称公司)投资者关系管理 工作，加强公司与投资者之间的有效沟通，促进公司完善治理，提高上市公司质 量，切实保护投资者特别是中小投资者合法权益，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司投资者关系管理工作指引》《上海证券交易 所上市公司自律监管指引第 1 号——规范运作》等有关法律法规，结合公司实际 情况，制定本制度。 第二章 投资者关系管理的原则与目的 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的基本原则： （一）充分披露信息原则：除强制的信息披露以外，公司可根据具体情况主 动披露投资者关心的其他相关信息； （二）合规性原则：公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律、法 ...

注册地址：北京市海淀区知春路20号中国医药大厦7层 法定代表人：王鹏 上海现代制药股份有限公司 关于国药集团财务有限公司 2025 年半年度 风险持续评估的报告 根据《上海证券交易所上市公司自律监管指引第 5 号—交易与关联交易》的 要求，上海现代制药股份有限公司（以下简称国药现代）通过查验国药集团财务 有限公司（以下简称国药财务）的《企业法人营业执照》与《金融许可证》等资 料，并审阅了国药财务截至 2025 年 6 月 30 日的财务报告以及风险指标等必要信 息，对国药财务的经营资质、业务和风险状况进行了评估，具体情况报告如下： 一、国药财务基本情况 国药财务成立于2012年2月23日，是经原中国银行业监督管理委员会批准成 立的非银行金融机构。 企业名称：国药集团财务有限公司 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 业务范围：（一）吸收成员单位存款；（二）办理成员单位贷款；（三）办理 成员单位票据贴现；（四）办理成员单位资金结算与收付；（五）提供成员单位委 托贷款、债券承销、非融资性保函、财务顾问、信用鉴证及咨询代理业务；（六） 从事同业拆 ...

一、诉讼基本情况概述 2017 年 3 月，上海现代制药股份有限公司（以下简称公司）全资子公司国 药集团威奇达药业有限公司（以下简称国药威奇达）收到印度德里高等法院传票， DSM SINOCHEM PHARMEUTICALS NETHERLANDS B.V. （ 现 已 更 名 为 CENTRIENT PHARMACEUTICALS NETHERLANDS B.V.以下简称中化帝斯曼） 向印度德里高等法院提起诉讼，认为国药威奇达在生产阿莫西林产品过程中使用 的生产技术侵犯了中化帝斯曼在印度的专利 IN247301，要求法院对国药威奇达 专利侵权事项发布永久禁令，禁止国药威奇达在印度生产、使用、制造、配送、 销售、许诺销售、或直接及间接经营用该专利方法生产的阿莫西林三水合物。 2017 年 5 月 24 日，国药威奇达收到印度德里高等法院禁令，禁止国药威奇 达在印度生产、使用、制造、配送、销售、许诺销售、或直接及间接经营用印度 专利 IN247301 方法生产的阿莫西林三水合物。该禁令自颁布时点至进入实质审 理程序审议并作出判决之间生效（详见公司于 2017 年 5 月 26 日披露的 2017-041 号公告 ...

Financial Performance - The company's operating revenue for the first half of the year was approximately CNY 4.88 billion, a decrease of 18.16% compared to the same period last year[21]. - The total profit for the reporting period was approximately CNY 924.93 million, down 14.86% year-on-year[21]. - The net profit attributable to shareholders was approximately CNY 672.07 million, reflecting a decline of 6.46% compared to the previous year[21]. - The net cash flow from operating activities was approximately CNY 667.98 million, a significant decrease of 63.24% from the same period last year[22]. - The company's total assets at the end of the reporting period were approximately CNY 19.67 billion, a decrease of 1.46% compared to the end of the previous year[22]. - The basic earnings per share for the first half of the year was CNY 0.5011, down 6.46% year-on-year[23]. - The weighted average return on net assets was 4.96%, a decrease of 0.68 percentage points compared to the previous year[23]. - The company's operating revenue decreased by 18.16% year-on-year, amounting to approximately ¥4.88 billion, primarily due to lower sales and prices of penicillin raw materials and intermediates, as well as a decline in the formulation business[53]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares, totaling 134,117,269.20 yuan based on the total share capital of 1,341,172,692 shares as of June 30, 2025[6]. - The company aims to achieve a cash dividend of 403 million yuan for 2024, representing 37.13% of the net profit attributable to shareholders, with an increase of 268 million yuan compared to 2023[68]. - The company has increased its cash dividend payout ratio by 17.75 percentage points compared to 2023, reflecting a strong commitment to shareholder returns[68]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[10]. - The company has outlined potential risks and countermeasures in the management discussion section of the report[10]. - The report includes a forward-looking statement risk declaration, emphasizing the need for investors to recognize risks associated with future plans[7]. - The company faces market competition risks and industry policy risks, which may impact cost and revenue growth, and plans to optimize product strategy and enhance market response capabilities[61]. - The company has implemented a comprehensive risk prevention system for environmental protection, aiming to enhance its core competitiveness in this area[64]. Corporate Governance - The board of directors was fully present at the meeting to approve the report[4]. - The report indicates that the financial report is guaranteed to be true, accurate, and complete by the company's responsible persons[3]. - The company guarantees to participate in shareholder meetings and exercise rights and obligations equally, without seeking improper benefits from its shareholder status[81]. - The company will maintain independence in personnel, assets, finance, and operations from its controlling entities, ensuring no harm to the listed company's rights[82]. Industry Overview - The pharmaceutical manufacturing industry in China saw a revenue decline of 1.2% year-on-year, with total profits down 2.8%[27]. - The number of pharmaceutical manufacturing enterprises in China decreased to 9,791, marking the first decline in five years[27]. Product and Market Strategy - The company operates in various therapeutic areas, including anti-infection, cardiovascular, and oncology, with over 30 dosage forms available[29]. - The company is focusing on five core therapeutic areas: anti-infective drugs, cardiovascular drugs, anesthetics and psychotropic drugs, anti-tumor and immune modulators, and metabolic and endocrine drugs[32]. - The company is implementing a "three-in-one" sales model combining distribution, agency, and academic promotion, with a nationwide distribution network established[33]. - The company is actively pursuing a strategy of supply chain integration and digital procurement management to enhance procurement efficiency and bargaining power[63]. Research and Development - The company obtained 31 research achievements, including drug registration certificates and consistency evaluations, representing a year-on-year increase of 29.17%[39]. - The company plans to enhance its research and development capabilities by increasing R&D investment and optimizing the management system, with 27 new research projects initiated and 2 clinical approvals for improved new drugs obtained in 2025[66]. - Research and development expenses decreased by 6.17% year-on-year to approximately ¥230 million, with the proportion of R&D investment to operating revenue increasing by 0.62 percentage points[55]. Financial Position - The company's total liabilities decreased to CNY 3.99 billion from CNY 4.63 billion in the previous period, reflecting a reduction of approximately 13.8%[112]. - Current assets totaled CNY 10.90 billion, down from CNY 11.68 billion, indicating a decline of about 6.7%[110]. - Cash and cash equivalents were reported at CNY 4.70 billion, a decrease of 24.3% from CNY 6.21 billion at the end of 2024[110]. - The company's equity attributable to shareholders rose to CNY 13.64 billion, compared to CNY 13.20 billion, reflecting an increase of about 3.3%[112]. Compliance and Legal Matters - There are no significant litigation or arbitration matters reported during the reporting period[85]. - The patent infringement lawsuit involving the company's subsidiary and a third party has been officially concluded as of January 2023[85]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[85]. Accounting Policies - The financial statements are prepared based on the going concern assumption, with no significant doubts about the company's ability to continue operations for the next 12 months[145]. - The company adheres to specific accounting policies for financial instruments, inventory, fixed assets depreciation, and revenue recognition, ensuring compliance with accounting standards[146][147]. - The company uses a perpetual inventory system and applies the weighted average method for inventory valuation[183].

Core Insights - The company reported a revenue of 4.878 billion yuan for the first half of 2025, representing a year-on-year decline of 18.16% [1] - The net profit for the same period was 672 million yuan, showing a decrease of 6.46% compared to the previous year [1] - A total cash dividend of 134 million yuan (including tax) will be distributed based on a total share capital of 1.341 billion shares as of June 30, 2025 [1]

为优化资产结构和资源配置，提高资产运营效率，促进高质量发展，上海现 代制药股份有限公司（以下简称公司）于 2025 年 7 月 30 日在上海联合产权交易 所公开挂牌转让控股子公司上海现代哈森（商丘）药业有限公司（以下简称国药 哈森）51%股权，首次挂牌底价为国药哈森 51%股权对应评估价值人民币 15,519.2541 万元（详见公司 2025-059 号公告）。 二、交易进展情况 上海现代制药股份有限公司 关于公开挂牌转让控股子公司股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 证券代码：600420 证券简称：国药现代 公告编号：2025-062 2025 年 7 月 30 日，"上海现代哈森（商丘）药业有限公司 51%股权"项目 在上海联合产权交易所首次正式挂牌，首次挂牌转让底价为人民币 15,519.2541 万元。截至本次转让公开信息披露（挂牌）首轮期满，即 2025 年 8 月 27 日，未 征集到合格意向方。公司于 2025 年 8 月 28 日以评估价的 90%第二次挂牌转让国 ...

Group 1 - The animal vaccine sector experienced a decline of 0.72% as of the market close on August 22, ranking among the top declines in concept sectors [1] - Within the animal vaccine sector, companies such as Shenlian Biological, Weilan Biological, and Xianfeng Holdings saw significant declines, while Kexing Pharmaceutical, Haizheng Pharmaceutical, and Guoyao Modern recorded increases of 2.06%, 0.44%, and 0.09% respectively [1] - The overall market saw a net outflow of 0.68 billion yuan from the animal vaccine sector, with 11 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net outflow in the animal vaccine sector was from Kanghua Biological, with a net outflow of 30.50 million yuan, followed by Shenlian Biological, Dabeinong, and Jinhai Biological with outflows of 27.38 million yuan, 24.27 million yuan, and 23.53 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Luoniushan, with net inflows of 27.34 million yuan, 16.70 million yuan, and 10.38 million yuan respectively [3] - The trading activity in the animal vaccine sector showed that Kanghua Biological had a turnover rate of 3.52% and a decline of 1.70%, while Kexing Pharmaceutical had a turnover rate of 3.12% and an increase of 2.06% [3]

Group 1 - The restructuring protein concept declined by 0.85%, ranking among the top declines in the concept sector, with leading decliners including Beida Pharmaceutical, Saiseng Pharmaceutical, and Rejing Bio [1][2] - Among the 39 stocks in the restructuring protein sector, 18 stocks saw price increases, with Zhongyuan Qihua, Huaxi Bio, and *ST Wanfang leading the gains at 3.27%, 2.53%, and 2.23% respectively [1][2] - The restructuring protein sector experienced a net outflow of 789 million yuan from main funds today, with Shenzhou Cell seeing the largest outflow of 75.26 million yuan [2][3] Group 2 - The top gainers in the concept sector included Tonghuashun Fruit Index at 3.70%, AI Mobile at 2.77%, and National Big Fund Holdings at 2.76%, while the monkeypox concept declined by 0.86% [2] - The main funds saw net inflows in stocks such as Huaxi Bio, Guoyao Modern, and Haoyuan Pharmaceutical, with inflows of 47.54 million yuan, 21.85 million yuan, and 20.45 million yuan respectively [2][4] - The restructuring protein concept's outflow list included stocks like Shenzhou Cell, Ruizhi Pharmaceutical, and Kexing Pharmaceutical, with respective outflows of 75.26 million yuan, 70.92 million yuan, and 65.90 million yuan [2][3]